Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
17 December 2018 | Story Xolisa Mnukwa
Karla takes netball world by storm
Karla Pretorius, vice-captain of the Protea netball team, has become a leading player in world netball.

The University of the Free State (UFS) has produced a number of exceptional netball players over the years, but none quite on the level of Karla Pretorius, who is widely considered as probably the very best in her position.

 

A whole new level


Pretorius, who is completing her postgraduate studies in Dietetics, was already deemed one of the best when she left for Australia at the end of 2016; however, she has since risen to a whole new level. The Protea vice-captain plays for the Sunshine Coast Lightning in Australia’s Suncorp Super Netball league, the world’s leading competition. She is scheduled to return there again next year. Karla comfortably leads the stats with a total of 50 intercepts and was named in the Team of the Tournament.

 

According to the former Australian coach, Norma Plummer, who is now at the helm of the Proteas, “Karla currently has to be one of the best, if not the best, goal defenders playing at this moment in time.”

 

Karla’s ability to come through with speed-anticipating interceptions is something that is so exciting to watch. She is very versatile and can switch from one-on-one to split circle or other defensive styles, explained Norma. She says Karla is light in stature but physically very strong.

 

Keep on improving

 

According to Pretorius, who played for the Kovsies between 2009 and 2015, playing in an environment where every possible aspect gets attention – with emphasis on detail – has benefited her immensely. “Everything is done so professionally to eventually push you to become the best possible player.” Karla explained that she experiences challenges in many fields of her life but has the chance to play with and against the best players with different skills, which helps her to keep on improving and bettering her craft.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept